Study Comparing Xaluritamig Plus Abiraterone to Other Treatments in Patients with Advanced Prostate Cancer

Inclusion Criteria

• Must provide informed consent before starting any study-related activities.
• Must be 18 years or older.
• Must have a confirmed diagnosis of prostate cancer that has spread and is resistant to hormone therapy.
• Must have at least one cancerous lesion visible on a scan taken within 28 days before joining the study.
• Must show signs of cancer progression, such as increased PSA levels or new lesions on scans.
• Must have had surgery to remove the testicles or be on ongoing hormone therapy to lower testosterone levels.
• Must have previously tried one androgen receptor pathway inhibitor (like enzalutamide, apalutamide, or darolutamide) and experienced disease progression.
• If planning to receive cabazitaxel, must have had no more than 6 cycles of docetaxel in the past.
• Must be in good overall health with an ECOG performance status of 0 or 1.
• Must have adequate organ function.

Exclusion Criteria

• History of cancer spread to the brain or spinal cord.
• Unresolved side effects from previous cancer treatments, except for hair loss or stable, well-controlled side effects.
• Previous treatment with STEAP1-targeted therapy.
• Previous intolerance or progression on abiraterone.
• Previous chemotherapy for advanced prostate cancer or more than 6 cycles of docetaxel for hormone-sensitive prostate cancer.
• Any cancer treatment, immunotherapy, or experimental drug within 4 weeks before starting the study, except for hormone therapy.
• Previous PSMA radioligand therapy within 3 months before starting the study.
• Previous radionuclide therapy within 2 months before starting the study.
• Previous palliative radiotherapy within 2 weeks before starting the study, unless fully recovered from side effects.
• Concurrent use of chemotherapy, ARPI, immunotherapy, radioligand therapy, PARP inhibitors, biological therapy, or experimental therapy.
• Recent vaccination with live or live-attenuated vaccines within 4 weeks before starting the study.